Dr. Paul Auwaerter discusses the BA.2 Subvariant and the recent authorization from the FDA for second booster dose. Topics: *Virulence of BA.2 vs Omicron and Delta * Therapeutic activity of monoclonal antibodies against BA.2 *Details of approval for booster #2 (4th and 5th dose) *Are there advantages to mixing mRNA vaccines?
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine